CriticalSelective serotonin reuptake inhibitors (SSRIs)×Serotonin antagonist and reuptake inhibitor (SARI) antidepressant
Updated · Methodology
Mechanism
Escitalopram prolongs the QT interval in a dose-dependent way (escitalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Trazodone also prolongs the QT interval, and its adverse reactions include torsade de pointes (trazodone label, US Food and Drug Administration, FDA, and trazodone SmPC, AEMPS). No study has tested this pair, but the documents of both drugs warn that the effects on QT may add up (escitalopram SmPC, AEMPS; trazodone FDA label). Both drugs increase serotonin activity. The trazodone SmPC describes serotonin syndrome in people who took trazodone with selective serotonin reuptake inhibitors (SSRIs), the group escitalopram belongs to (AEMPS). The liver forms the active metabolite of trazodone mainly through the enzyme CYP3A4, and escitalopram at 20 mg does not inhibit this enzyme (trazodone SmPC, AEMPS; escitalopram FDA label).
Symptoms
QT interval prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). Torsade de pointes, a ventricular tachycardia, causes palpitations, dizziness and fainting. With escitalopram, such arrhythmias were reported mainly in women and in people with low potassium, a pre-existing long QT interval or other heart disease (escitalopram summary of product characteristics, SmPC). Serotonin syndrome presents with agitation, tremor, muscle jerks and fever (escitalopram SmPC). Hallucinations, a fast pulse, unstable blood pressure, sweating, nausea, vomiting and diarrhoea may also occur (trazodone label, US Food and Drug Administration, FDA). Trazodone causes somnolence and a drop in blood pressure on standing, sometimes with fainting, more often in older people (trazodone SmPC).
Management
The combination is contraindicated because escitalopram must not be used with other drugs that prolong the QT interval (escitalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Trazodone prolongs QT according to its own documents (trazodone label, US Food and Drug Administration, FDA, and trazodone SmPC, AEMPS). The trazodone FDA label says to avoid combining it with QT-prolonging drugs, while the Spanish trazodone SmPC asks for caution (trazodone FDA label and AEMPS SmPC). The UK National Institute for Health and Care Excellence (NICE) lists adding trazodone to a selective serotonin reuptake inhibitor (SSRI) as an option when depression has had no response or a limited response to an antidepressant. NICE also advises considering referral to a specialist mental health service or consulting a specialist, and explaining to the patient in advance that side effects may increase (NICE NG222). If the patient still takes both drugs, correct low potassium and magnesium before starting escitalopram, and consider an electrocardiogram (ECG) before the start in stable heart disease (escitalopram SmPC, AEMPS). If signs of arrhythmia appear, stop escitalopram and record an ECG (escitalopram SmPC, AEMPS). Avoid trazodone in people with a history of arrhythmias, symptomatic bradycardia, low potassium or magnesium, or congenital QT prolongation (trazodone FDA label). Somnolence and orthostatic hypotension from trazodone can add to the effects of other psychotropic drugs, especially in older people. Warn the patient or carer and watch these effects closely after the start and before and after each dose increase (trazodone SmPC, AEMPS). Monitor for serotonin syndrome, particularly at the start of escitalopram and after dose increases (escitalopram FDA label). If it appears, stop both drugs at once and start symptomatic treatment (escitalopram and trazodone SmPCs, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Lexapro (escitalopram) prescribing information (2023)– FDA label, Allergan, Inc., DailyMed setid 13bb8267-1cab-43e5-acae-55a4d957630a, revised 10/2023, sections 4, 5.2 and 7
- AEMPS: Ficha técnica: Trazodona (nº registro 78585), sección 4.5 (2026)– AEMPS, CIMA, nº registro 78585 (Trazodona Normon 100 mg), revisión 06/2026, secciones 4.4 y 4.5
- FDA: RALDESY (trazodone hydrochloride) prescribing information (2026)– FDA, DailyMed setid 34708cc1-b0b2-4fd0-b9f3-7f008b457fc9 (Validus), revisión 09/2026 (versión 6), secciones 5.2, 5.3, 5.9 y 7
- AEMPS: Ficha técnica: Escitalopram (nº registro 65230), sección 4.3 (2026)– AEMPS, CIMA, nº registro 65230 (Cipralex 10 mg, Lundbeck), revisión 03/2026, secciones 4.3, 4.4 y 4.5
- NICE: Depression in adults: treatment and management (NG222), further-line treatment (2022)– NICE guideline NG222, published 06/2022, recommendations 1.9.8–1.9.9 (adding trazodone to an SSRI as a further-line option)